Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact
Authors:
- Federico M. GoodsaidFGFederico M. Goodsaid
- Shashi AmurSAShashi Amur
- Jiri AubrechtJAJiri Aubrecht
- Michael E. BurczynskiMBMichael E. Burczynski
- Kevin CarlKCKevin Carl
- Jennifer CatalanoJCJennifer Catalano
- Rosane CharlabRCRosane Charlab
- Sandra CloseSCSandra Close
- Catherine Cornu-ArtisCCCatherine Cornu-Artis
- Laurent EssiouxLELaurent Essioux
- Albert J. FornaceAFAlbert J. Fornace
- Lois HinmanLHLois Hinman
- 1 June 2010
- journal article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 9 (6) , 435-445
Abstract
Heterogeneity in the underlying mechanisms of disease processes and inter-patient variability in drug responses are major challenges in drug development. To address these challenges, biomarker strategies based on a range of platforms, such as microarray gene-expression technologies, are increasingly being applied to elucidate these sources of variability and thereby potentially increase drug development success rates. With the aim of enhancing understanding of the regulatory significance of such biomarker data by regulators and sponsors, the US Food and Drug Administration initiated a programme in 2004 to allow sponsors to submit exploratory genomic data voluntarily, without immediate regulatory impact. In this article, a selection of case studies from the first 5 years of this programme - which is now known as the voluntary exploratory data submission programme, and also involves collaboration with the European Medicines Agency - are discussed, and general lessons are highlighted.Keywords
This publication has 45 references indexed in Scilit:
- Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery diseaseEuropean Heart Journal, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cellsJournal of Translational Medicine, 2008
- Late Kidney Allograft LossClinical Journal of the American Society of Nephrology, 2008
- Qualification of Biomarkers for Drug Development in Organ TransplantationAmerican Journal of Transplantation, 2007
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Using RNA sample titrations to assess microarray platform performance and normalization techniquesNature Biotechnology, 2006
- Evaluation of DNA microarray results with quantitative gene expression platformsNature Biotechnology, 2006
- Hepatic Findings in Long-Term Clinical Trials of XimelagatranDrug Safety, 2005
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004